Iovance Biotherapeutics Inc (IOVA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.59B
Last updated: Nov 17, 2026 at 4:35 PM ET
Iovance Biotherapeutics Inc (IOVA) Statistics
Iovance Biotherapeutics (IOVA) has a market cap of $3.59B and an enterprise value of $3.53B. Its share count is up 25.24% from a year earlier. It kept -58.19% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 1.61% below the market cap, as cash exceeds debt.
| Market Cap | $3.59B |
|---|---|
| Enterprise Value | $3.53B |
| Latest price (Nov 17, 2026) | $7.53 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 9.1x and 4.2x.
| P/S Ratio | 9.1x |
|---|---|
| Forward P/S | 8.6x |
| P/B Ratio | 4.2x |
| P/TBV Ratio | 6.2x |
Price Statistics
The stock is up 204.86% over 52 weeks and trades 33.30% below its 50-day average.
| Beta (1Y) | 1.63 |
|---|---|
| 52-Week Change | +204.86% |
| 1-Month Change | -47.01% |
| 3-Month Change | -5.76% |
| 6-Month Change | +117.63% |
| 5-Year Change | -65.12% |
| 10-Year Change | +35.68% |
| Total Return (1Y) | +204.86% |
| Total Return (3Y CAGR) | +14.24% |
| Total Return (5Y CAGR) | -16.95% |
| Return vs SPY (1Y) | +197.05% |
| Max Drawdown (1Y) | -49.33% |
| Max Drawdown (3Y) | -90.50% |
| Sharpe Ratio (1Y) | 1.07 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $11.29 |
| 200-Day Average | $6.16 |
| 52-Week Range | $2.08 to $15.37 |
| RSI (14 Days) | 31.8 |
| Average Volume (20 Days) | 15.33M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.20x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.20x |
|---|---|
| Quick Ratio | 4.67x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -27.14% over the last 12 months, against a 5-year average of -63.72%.
| Return on Equity (ROE) | -27.14% |
|---|---|
| Return on Assets (ROA) | -22.25% |
| ROE (5Y Average) | -63.72% |
| ROA (5Y Average) | -48.85% |
| ROIC (5Y Average) | -56.25% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 2.93x |
| Receivables Turnover | 3.62x |
| Cash Conversion Cycle | 171 days |
Scores
IOVA has an Altman Z-Score of 7.56, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.56 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $378.98M over the last 12 months is up 51.34% from the 12 months before.
| Revenue | $378.98M |
|---|---|
| Revenue Growth (YoY) | +51.34% |
| Gross Profit | $216.56M |
| Operating Income | -$230.38M |
| Pretax Income | -$221.78M |
| Net Income | -$220.53M |
| EBITDA | -$192.16M |
| Reported EPS (TTM) | -$0.53 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 81.99% of the $991.21M in total assets.
| Cash and Equivalents | $57.93M |
|---|---|
| Total Debt | $0 |
| Net Cash | $57.93M |
| Net Cash Per Share | $0.13 |
| Working Capital | $443.86M |
| Shareholder Equity | $812.66M |
| Book Value Per Share | $1.78 |
| Tangible Book Value | $553.46M |
| Tangible Book Per Share | $1.21 |
| Total Assets | $991.21M |
| Total Liabilities | $178.55M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $26.11M of capital spending, operating cash flow left -$216.06M of free cash flow.
| Operating Cash Flow | -$189.95M |
|---|---|
| Capital Expenditures | $26.11M |
| Free Cash Flow | -$216.06M |
| FCF Per Share | -$0.48 |
| Depreciation and Amortization | $38.22M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -60.79%.
| Gross Margin | 57.14% |
|---|---|
| Operating Margin | -60.79% |
| Pretax Margin | -58.52% |
| Net Margin | -58.19% |
| EBITDA Margin | -50.70% |
| FCF Margin | -57.01% |
Dividends and Yields
IOVA does not pay a dividend. Its free cash flow yield is -6.29%.
| FCF Yield | -6.29% |
|---|---|
| Buyback Yield | -8.55% |
| Shareholder Yield | -8.55% |
Stock Splits
The last split was a 1-for-100 reverse split on Sep 26, 2013.
| Last Split Date | Sep 26, 2013 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:100 |
Peer Position
Against 9 similar companies, IOVA has the 7th highest P/S.
P/S RatioPeer median 13.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +29.42%
| P/S Ratio | 9.1x vs 13.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +51.34% vs +29.42% median |
Analyst Forecast
Consensus estimates put revenue growth at 50.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +50.12% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IOVA
What is IOVA's market cap?
Iovance Biotherapeutics has a market cap of $3.59B. Its enterprise value, which adds debt and subtracts cash, is $3.53B.
How many shares of IOVA are outstanding?
Iovance Biotherapeutics has 455.92M shares outstanding. The count is up 25.24% from a year earlier.
Does IOVA pay a dividend?
No. Iovance Biotherapeutics does not pay a dividend.
How much debt does IOVA have?
Iovance Biotherapeutics has $0 of total debt and $57.93M of cash and equivalents, a net cash position of $57.93M.
IOVA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts